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Abstract
Developments of non-viral carriers have headed toward reducing cytotoxicity, which results
from the use of conventional gene carriers, and enhancing gene delivery efficiency. Cys-
(D-R9)-Cys repeated reducible poly(oligo-D-arginine) (rPOA) is one of the most efficient
non-viral carriers for gene therapy; however, while its efficiency has been verified in the lung
and brain, it is necessary to confirm its activity in each organ or tissue since there are differ-
ences of gene carrier susceptibility to among tissue types. We therefore tested the compati-
bility of rPOA in cardiac tissue by in vitro or in vivo experiments and confirmed its high
transfection efficiency and low cytotoxicity. Moreover, substantial regenerative effects were
observed following transfection with rPOA/pVEGF expression vector complexes (79%
decreased infarct size) compared to polyethyleneimine (PEI) (34% decreased infarct size)
in a rat myocardial infarction (MI) model. These findings suggest that rPOA efficiently
enables DNA transfection in cardiac tissue and can be used as a useful non-viral therapeu-
tic gene carrier for gene therapy in ischemic heart disease.
Introduction
Gene therapy is one of the most innovative tools with broad potential application in disease
therapy, which might be feasible in the near future. About 450 clinical “gene therapy” trials
have been registered in the US National Clinical Trial Database, of which 50 were submitted as
studies involving “gene therapy and the heart” [1]. After the first approval of a gene-based ther-
apeutic approach in 2012 [2], several pharmaceutical companies have focused on the clinical
application of gene transfer technology, which was used in basic research. Besides canonical
gene therapy with viral or non-viral carriers, genome editing has been adopted as gene therapy
techniques that attract scientific concern [3]. However, its clinical application remains prema-
ture because its safety remains to be verified [4].
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Gene therapy vehicles can be classified as viral or non-viral carriers. Several non-viral carri-
ers with numerous new characteristics for gene delivery, including low immunogenicity, safety
from random integration into host chromosomes, and easy handling, have been developed [5].
Nevertheless, non-viral carriers are subject to various limitations, such as low transfection effi-
ciency and high toxicity, and temporal gene expression. To overcome these limitations, many
researchers focused their efforts on developing optimized enhanced gene carriers [6].
While cardiovascular diseases are promising targets for gene therapy, owing to their high
incidence and that only local gene delivery would be necessary to give rise to therapeutic effects
[7]. Polyethylenimine (PEI) is a general carrier used in gene transfer to cells or tissues, but is
toxic and its use in treatment can often result in cell death [8]. As such, several carriers have
been developed to replace PEI, including non-arginine (D-R9) which is known for its efficient
protein transduction domains (PTDs) that aid in the delivery of several biological materials
(DNA, RNA, proteins, and particles) [9]. Importantly, the Cys-(D-R9)-Cys repeat of reducible
poly(oligo- D -arginine) (rPOA) enhances its DNA transfection efficiency[10]. Although the
efficacy and toxicity of rPOA has been reported in the lung and brain [10–12], these have not
yet been evaluated in the heart.
Myocardial infarction (MI) is a primary cause of heart disease and occurs when blood flow
is limited by stenosis or occlusion of the coronary artery restricts the cardiac tissue from receiv-
ing sufficient oxygen or nutrients, resulting in cardiac injury [13]. Cardiac tissue injury by irre-
versible ischemia requires a lifetime of medical treatment. Many researchers have shown that
vascular endothelial growth factor (VEGF)-treated infarcted hearts exhibit improved heart
function, and thus can be utilized as molecular marker for analyzing gene carrier function
[14–16]. Moreover, VEGF secretion is enhanced by the hypoxia-responsive plasmid, pβ-signal
peptide-oxygen-dependent degradation-VEGF (pβ-SP-ODD-VEGF), which is induced by
post-translational regulation in response to the hypoxic conditions present in MI hearts [17].
In the present study, the feasibility rPOA/plasmid DNA (pDNA) polyplex treatment for MI
induced in rat hearts was investigated through a comparative analysis with conventional poly-
ethyleneimine (PEI)/pDNA complexes. These results suggested that rPOA was a suitable car-
rier for ischemic heart gene therapy.
Materials and Methods
Cell culture, in vitro transfection, and hypoxia induction
H9c2 rat cardiomyocytes were obtained from the Korean Cell Line Bank (Seoul, Korea) and
cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% (v/v) fetal bovine serum (FBS) at 37°C in a 5% CO2 incubator. For transfection assays, the
cells were seeded in wells or culture dishes 24 hours before the transfection. Cells were cultured
in serum-free medium for 30 min prior to transfection. For 6-well plates, a fixed amount of
plasmid (2 μg/well) was mixed with different ratios (1:1, 1:2, or 1:4) of polymer (2, 4, or 8 μg)
in 200 μL of phosphate-buffered saline (PBS), incubated at room temperature for 30 min, and
the mixtures were then added to the cells. PEI controls were mixed at a 1:1 ratio. After a 4 h
incubation at 37°C, transfected cells were replated in fresh working medium (10% FBS in
DMEM). Hypoxia was induced as previously described [18].
Luciferase assays and flow cytometry
To evaluate gene expression, pCMV-luc plasmid transfected cell lysates were monitored for
luciferase activity using a luciferase assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. For flow cytometry experiments, pEGFP-C1-transfected cells
were trypsinized, washed with PBS, and the resuspended cells were monitored by flow
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cytometry (FACSverse, BD science) with the appropriate filters. All experiments were per-
formed in triplicate.
Cytotoxicity assays
Cell viability was evaluated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay as described previously [19].
Rat myocardial infarction model construction and complex injection
In vivo experiments were performed with a rat MI model as described previously [19]. The
experimental protocol was approved by the Animal Research Committee of the University of
Yonsei (Permit Number: 2012–0202). Briefly, eight-week-old male Sprague-Dawley rats were
anesthetized by an intramuscular injection of ketamine hydrochloride (90 mg/kg) and xylazine
hydrochloride (5 mg/kg). After incision at the left lateral costal rib, the left anterior descending
coronary artery (LAD) was ligated with 6–0 silk for 1 h, followed by reperfusion. After surgery,
all rats were treated 1 mg/kg ketorolac and 5 mg/kg gentamicin via subcutaneous injection for
three days. One hour before reperfusion, 15 μg of plasmid in 50 μL PBS was administered to
the myocardium of randomly chosen mice at three sites around the ischemic border and one
site within the presumed central infarct region. For the in vivo gene expression analysis, ani-
mals were re-anesthetized and sacrificed for the fluorescence and histological analysis at three
days after surgery. Alternatively, animals were re-anesthetized and killed at one-week after
VEGF gene complex infusion to examine VEGF expression and for histological analysis. All
histological measurements were performed in blinded manner.
Fibrosis and infarct size analysis
Hearts were fixed in 10% formalin for 16 h at 2–8°C and then stained with hematoxylin and
eosin (H&E) and Masson’s trichrome to analyze tissue fibrosis. Fibrotic planimetry was per-
formed using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). To
measure the size of MI, hearts were sectioned transaxially and incubated in 1% 2,3,5-triphenyl-
tetrazolium chloride (Sigma, St. Louis, MO, USA) for 20 min at 37°C. The area of the left ven-
tricle and total collagen-stained area were measured using Image J. Left ventricle infarct size
was calculated as the ratio (%) of cumulative infarct area to the entire left ventricle area.
TUNEL assay
Apoptosis was evaluated using the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Che-
micon International, Temecula, CA, USA) according to the manufacturer’s instructions.
Briefly, a positive control sample was prepared from a normal heart section treated with 10 U/
mL DNase I for 20 min at room temperature. Sections were pretreated with 3.0% H2O2, reacted
with terminal deoxynucleotide transferase enzyme at 37°C for 1 h, followed by incubation with
digoxigenin-conjugated nucleotide substrate at 37°C for 30 min. After incubation for 5 min in
3,3-diaminobenzidine (DAB), nuclei exhibiting DNA fragmentation turned dark brown. Tis-
sue sections were counterstained with hematoxylin, mounted, and observed by light micros-
copy. Five high magnification fields (400×) were examined in each of five sections per group,
and the mean of these five measurements was determined (n = 5/group).
Immunohistochemistry
Immunohistochemistry experiments were performed as previously described [11]. Monoclonal
antibodies against CD31 (Abcam, Cambridge, MA, USA) and human VEGF (Abcam) were
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used at 1:100. The number of CD31-positive cells per mm2 was counted in whole sections at
100× magnification in a blinded manner. Images were analyzed using Image J.
Statistical analysis
Data were analyzed using Student’s t-test and presented as the mean ± SD of independent mea-
surements (n> 3 samples/group). P values< 0.05 were considered as statistically significant.
Results
Suitability of reducible poly(oligo-d-arginine) for rat cardiomyocyte
transfection
To examine the suitability of rPOA for cardiac gene delivery, H9c2 cardiomyocytes were trans-
fected with different rPOA/pDNA ratios (1:0.5, 1:1, 1:2, and 1:4) and analyzed by gel retarda-
tion assay. The rPOA conjugates showed complete pDNA condensation at ratios> 1:2 (S1A
Fig). The surface properties of these complexes—i.e., particle size, zeta potential, and size distri-
bution—were then investigated. When the weight ratio was> 1:2, the co-polymer completely
condensed the DNA and the pDNA size was 170.1 nm (S1B Fig). Moreover, the zeta potentials
of the complexes peaked at 43.4 mV resulting from polycation saturation (S1C and S2 Figs).
The rPOA/pDNA weight ratio complexes applied to the H9c2 cells and compared to PEI
control transfections in luciferase activity assays. Notably, the relative luciferase activity of 1:2
rPOA/pCMV-luc complex-transfected H9c2 cells were similar to that observed in PEI/pCMV-
luc complex-transfected cells, but were much higher than the naked DNA- or 1:1 rPOA/
pCMV-luc complex-transfected groups (Fig 1A). To confirm the results of the luciferase assay,
EGFP-C1-transfected H9c2 cells were analyzed by fluorescence microscopy following transfec-
tion with rPOA/pDNA complexes at 1:2 and 1:4 weight ratios. This analysis revealed that a
lower number of GFP-expressing cells were detected in the rPOA/pEGFP-C1 complex-trans-
fected group than in PEI/pEGFP-C1 control transfections (Fig 1B). These findings were further
confirmed by flow cytometry (Fig 1C), which showed that while ~26% of cells expressed GFP
in PEI/pEGFP-C1 transfections, only 9% of cells were positive in the rPOA/pEGFP-C1-trans-
fected cultures.
To determine the cytotoxic effects of these gene carrier complexes, MTT assays were per-
formed with the same experimental groups detailed above (Fig 1D). When 1:2 rPOA/pDNA
complexes were applied to H9c2 cells, which showed a transfection efficiency similar to that of
the PEI/pDNA complexes, 98% of cells were viable, whereas only 50.78% of PEI/pDNA- trans-
fected cells survived. These data indicate that rPOA shows high transfection efficiency and low
toxicity for cardiomyocytes and is suitable carrier for gene delivery in cardiac cells.
Enhanced in vivo gene delivery efficiency with rPOA
To determine the effect of the rPOA/pDNA complexes in vivo, rPOA/pEGFP-C1 complexes at
the optimized 1:2 ratio were injected into rat hearts to compare the gene delivery efficiency
with the PEI/pEGFP-C1 complexes in vivo. Three days post-injection, green fluorescence
imaging of sliced tissues revealed positive GFP expression (Fig 2). A representative image is
shown in Fig 2A, and total GFP expression was quantified and presented in Fig 2B. Notably,
the proportion of GFP-positive tissue in rPOA/pEGFP-C1 and PEI/pEGFP-C1 complex-trans-
fected hearts were 26.212 ± 3.271 mm2 and 5.773 ± 2.637 mm2, respectively.
Cytotoxicity was also analyzed in response to PEI and rPOA treatment in myocardium tis-
sues by monitoring immune cell infiltration with H&E analysis. As expected, the cytotoxic
effects of each carrier led to an induction of cell infiltration in target tissues as shown in the
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arrows indicated area in Fig 2C which shows representative images of immune cell infiltration.
In order to analyze these data statistically, all nuclear-stained cells were counted, including all
cardiomyocytes. A saline treated group served as normal control (2981.48 ± 150.85 cells/mm2).
Analysis of the PEI-treated group revealed an increase of ~50% in the cell population
(4537.04 ± 283.79 cells/mm2). Conversely, a similar but slightly increased cell population was
calculated in the rPOA-treated group (3114.82 ± 373.89 cells/mm2).
Application of rPOA in rat model of MI
Visualization of VEGF expression by pβ-SP-ODD-VEGF (pVEGF) were verified at the border
zone of ischemic cardiac tissue by immunohistochemistry against VEGF proteins (Fig 3). As
expected, much higher VEGF expression was detected in the rPOA/pVEGF-injected infarct
region than in PEI/pVEGF or control MI group (saline-injected group) (Fig 3A). Quantitative
analysis of VEGF immunoreactivity is shown in Fig 3B. Notably, VEGF protein expression was
2.5 fold higher in rPOA/pVEGF-injected tissue than PEI/pVEGF controls (Saline: 135.98 ±
18.58 μm2; PEI/pVEGF: 781.41 ± 121.68 μm2; and rPOA/pVEGF: 2168 ± 2.7 μm2). These data
are consistent with the in vivo GFP expression observed in Fig 2.
Fig 1. In vitro transfection efficiency and cytotoxicity of rPOA as a gene carrier. (A) Optimization of pCMV-Luc transfection into H9c2 cardiomyocytes
using three different weight ratios (1:1, 1:2, and 1:4) of rPOA and PEI25K (1:1) as a positive control. Transfection efficiencies were measured by luciferase
assay. Data are expressed as the mean ± SD of three experiments. *P < 0.001 vs. PEI. (B) Green fluorescence protein (GFP) expression in rPOA-
transfected H9c2 cardiomyocytes. pEGFP-C1 plasmids were mixed with indicated carrier and ratio. A 465–495 nm excitation filter was used to detect GFP
expression. (C) GFP-expressing cells were analyzed by flow cytometry to determine the percentage of GFP-expressing cells. (D) Cytotoxicity of rPOA vs.
PEI in H9c2 cells. Polymer/pDNA complexes were transfected into H9c2 cells, and cell viability was measured 24 h later by MTT assay. Data are expressed
as the mean ± SD. *P < 0.005 vs. control and PEI transfections.
doi:10.1371/journal.pone.0144491.g001
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To compare the differences of infarct size among VEGF expression plasmid-injected tissues,
the tissues were stained with triphenyltetrazolium chloride (TTC) to highlight the infarcted
region with a pale yellow color (Fig 4A). MI-induced hearts were injected with saline, PEI/
pVEGF, or rPOA/pVEGF and quantitatively assessed by measuring the area of infarcted tissue
area relative to the whole section (Fig 4B). MI-induced cardiac tissue contained approximately
40% of an infarcted region. Notably, the infarct size of PEI/pVEGF-injected tissue decreased to
25.352% ± 2.05% relative to the whole sections. Interestingly, rPOA/pVEGF-injected cardiac
tissue revealed an 8.122% ± 0.87% reduction in infarcted tissue. Furthermore, the extent of car-
diac fibrosis was analyzed by Masson’s trichrome staining, in which the collagen fibers appear
blue (Fig 4C). The percentages of fibrotic area to the left ventricle area were calculated and dis-
played in Fig 4D. The fibrotic area of saline-injected cardiac tissue was 38.13% ± 6.2%, whereas
the PEI/pVEGF-injected cardiac tissue was 17.47% ± 2.78%. Predictably, the fibrosis in rPOA/
pVEGF-injected cardiac tissue comprised 6.59% ± 2.02% of the images, which is only 17.29%
of that observed in controls.
TUNEL assays were subsequently used to evaluate the extent of cell death at 1 week after
LAD ligation. Notably, the number of TUNEL-positive cells in the infarct region was markedly
Fig 2. In vivo transfection efficiency and cytotoxicity of rPOA as a gene carrier. (A) Representative cardiac tissue sections with H&E staining and GFP
fluorescence analysis 3 days after injection of pEGFP-C1, PEI/GFP, or rPOA/GFP into rat hearts (400× magnification). Scale bar, 100 μm. (B) Quantitative
analysis of GFP expression across different groups. *P < 0.005, **P < 0.001 vs. control. (C) H&E staining of saline-, PEI-, or rPOA-injected rat myocardial
tissue. (D) Quantitative analysis of nuclear stained cells as a measure of left ventricular cellular infiltration post injection with saline (n = 4), PEI (n = 5), or
rPOA (n = 6). **P < 0.001 between groups.
doi:10.1371/journal.pone.0144491.g002
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lower upon injection of rPOA/pVEGF as compared to PEI/pVEGF (13.44% ± 3.01% vs. 36.8%
± 1.45% TUNEL-positive cells/mm2) (Fig 4E and 4F). To validate direct effects of transferred
VEGF gene were measured through angiogenic effects under the direct influence of VEGF.
Newly generated capillaries were detected by immunohistochemistry with a CD31 antibody
(Fig 4G and 4H). Compared to saline- and PEI/pVEGF-injected groups (3.9 ± 1.13 μm2 and
10.92 ± 1.05 μm2, respectively), rat hearts injected with rPOA/pVEGF (20.64 ± 1.2 μm2)
showed a significant increase in micro vascularization within the infarcted myocardial tissue.
These data indicate that rPOA/pVEGF transfected cells expressed more VEGF in to the ische-
mic myocardium than PEI/pVEGF counterparts, resulting in increased capillary generation.
Discussion
As previously reported, rPOA is one of the most effective non-viral carrier for gene delivery to
cultured cells or tissues [10, 12]; however, the efficacy of gene carrier delivery varies according
to the cell or tissue type. Gene expression levels in rPOA/pCMV-luc complexes transfected
cells measured by luciferase assay showed a similar luciferase activity to that of PEI/pCMV-luc
complex-transfected cells, but the analysis of GFP expression by flow cytometry yielded differ-
ent results since the proteins expressed by transfected gene are the primary therapeutic media-
tors; thus, a proper evaluation of gene therapy efficiency must be estimated by the amount of
protein expressed by the entire cell population, rather than the percentage of cells that express
the transfected gene.
Fig 3. Therapeutic application of rPOA in rat MI model with VEGF expression. (A) VEGF expression in the rat myocardium 1 week after the injection of
PEI/pVEGF or rPOA/pVEGF complexes, as visualized by anti-VEGF antibody labeling (200×). Red arrows indicated brown staining of VEGF expression. (B)
Quantitative analysis of VEGF immunoreactivity per mm2 tissue. Average values were obtained from five random high magnification fields in the infarct
border zone from each animal. Data represent mean ± SD. *P < 0.05.
doi:10.1371/journal.pone.0144491.g003
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The ultimate purpose of gene therapy is clinical application for the treatment of human dis-
ease; therefore, the cytotoxicity of the gene carrier is crucial factor to consider. MTT assay
showed that rPOA/pDNA-transfected cells exhibited a significantly higher viability (98%) than
that observed with PEI/pDNA-transfected counterparts (50.78%). Interestingly, the cells trans-
fected with PEI complexes had to be trypsinized for much longer in order to fully detach from
the culture plates, than rPOA-transfected cells. This phenomenon might provide a clue for the
Fig 4. Histological analysis of gene therapy-treated MI hearts. (A) Representative picture of myocardial sections stained with 2,3,5-triphenyltetrazolium
chloride (TTC). Pale yellow indicates infarct region. (B) Ratio of infarcted to non-infarcted left ventricular myocardium (%) from LAD-ligated rats injected with
saline, PEI/pVEGF, or rPOA/pVEGF (n = 5/group). *P < 0.0005, **P < 0.00001 vs. saline. (C) Representative myocardium sections stained with Masson’s
trichrome (lower panel, 200×). Scale bar, 200 μm. (D) Percent of myocardial collagen fibrosis expressed as the ratio of fibrotic area to left ventricle area in
LAD-ligated rats injected with saline, PEI/pVEGF, or rPOA/pVEGF (n = 5/group). *P < 0.005, **P < 0.00001. (E) Myocardial sections labeled with an
antibody against CD31 to detect neovascularization 1 week after injection (400×). Scale bar, 100 μm. (F) Quantitative analysis of CD31-positive cells in
ischemic myocardia treated with saline, PEI/pVEGF, or rPOA/pVEGF (n = 5/group). *P < 0.05, **P < 0.005.
doi:10.1371/journal.pone.0144491.g004
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increased toxicity of PEI. Although the transfection efficiency of rPOA/pDNA complexes was
sufficient to express genes in vitro, these findings do not always extend to in vivo transfections.
The analysis of rPOA/pEGFP-C1 complexes and PEI/pEGFP-C1 complexes in vivo revealed a
much larger proportion of cardiac tissue with GFP expression in rPOA/pEGFP-C1-injected
hearts (26212.95 μm2 ± 3271.67 μm2) than PEI/pEGFP-C1-injected counterparts (5773.74 ±
2637.52 μm2). While the in vitro transfection efficiency of rPOA in H9c2 cells is almost same
or lower than that observed with PEI, a substantial increase in gene expression was detected in
rPOA complex-injected heart tissue. The cardiac tissue contains smooth muscle cells, endothe-
lial cells, epicardial cells, fibroblasts, cardiomyocytes, and pacemaker cells [20], each with their
own distinct susceptibility to DNA/carrier complex uptake, which may account for the incon-
sistencies between our in vitro and in vivo data.
The pβ-SP-ODD-VEGF plasmid is post-translationally regulated to induce VEGF expres-
sion under hypoxic condition [21]. Oxygen deprivation during infarction elicits VEGF protein
expression from the pβ-SP-ODD-VEGF plasmid, whereas the protein is rapidly degraded via
oxygen-dependent degradation domain during normoxic conditions [22]. In vitro and in vivo
transfections with hypoxic H9c2 cells and ischemic myocardial tissue revealed that this oxy-
gen-responsive system was accurately regulated (S2 Fig). As expected, a markedly higher effi-
ciency of gene delivery was verified with VEGF and GFP detection in rPOA/pVEGF-injected
infarcted regions than in PEI/pVEGF or control MI (saline-injected) groups. We analyzed the
area of the VEGF positive signal not the number of VEGF expressed cells, because VEGF165,
which we used, is delivered to the surroundings from the cells. When the VEGF was expressed
in infarcted myocardium, these regions diminished concurrent with improvements in heart
function [23]. MI induced cardiac tissue shows about 40% of left ventricle are infarcted (saline
injected group). While infarct size in PEI/pVEGF injected tissue (25.352% ± 2.05%) was
decreased in about 34% relative to saline-injected tissue, infarct size in rPOA/pVEGF-injected
cardiac tissue showed a 79% decrease relative to saline-injected control tissue. Moreover, the
extent of cardiac fibrosis revealed a pattern similar to that of TTC staining (Fig 4C), which
related to the low number of cells with express transfected gene expression by flow cytometry,
but with a high mean value of gene expression in luciferase assays. Gene carrier functions are
dependent on two steps; (i) complex formation with nucleic acid, and (ii) penetration of gene
into the cells. The number of the transfected cells is dependent on the penetrating ability of the
complex in the susceptible point of view, where as its formation determines how many mole-
cules are transferred to a cell in the complex itself available point of view. Therefore, these
results suggest that the penetration efficiency is better in PEI complexes, whereas while the
complex formation capacity and safety against toxicity is better in rPOA complexes. Thus, the
efficient transfer and elevated expression of a gene delivered with rPOA is directly correlated
with improved therapeutic effects.
In general, apoptosis is induced in response to MI in human or animal models [24]. The
degree of apoptosis can be quantified by counting the number of TUNEL positive cells. As
expected, TUNEL-positive cells decreased in rPOA/pVEGF-injected heart tissue. According to
these data, although rPOA or PEI affect tissue cytotoxicity, it can be overcome through these
therapeutic complexes, suggesting that cell death can minimized in a PEI- or rPOA-treated
infarction model.
In this study, we optimized the gene delivery conditions to treat MI model rats using rPOA/
pDNA polyplexes. Nevertheless, the number of genes transferred to cells is low, whereas high
gene expression was detected in vitro. Furthermore, the rPOA/pDNA had higher transfection
efficiency and much lower cytotoxicity than PEI complexes in vivo, which subsequently
enhanced neovascularization and cardiac tissue repair. Collectively, these data suggest that
rPOA is one of primary candidates for clinical gene therapy with its highly efficient gene
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delivery efficiency and low cardiac toxicity; however, the comparative advantage of rPOA over
the other gene carrier systems should be continually assessed.
Supporting Information
S1 Fig. Characterization of rPOA/pVEGF polyplexes. (A) Gel retardation assay of rPOA/
pVEGF polyplexes prepared at various weight ratios. (B, C) Sizes and zeta-potentials of rPOA
polyplexes. (D) Size distribution as a function of intensity. Data represent the mean ± SD.
rPOA, reducible poly(oligo-D-arginine).
(TIF)
S2 Fig. VEGF expression levels in hypoxic and ischemic H9c2 cells and myocardium. (A)
VEGF expression in cells transfected with rPOA or PEI carriers under normoxic and hypoxic
conditions. VEGF expression levels were measured by ELISA. P< 0.001, P< 0.00001 vs.
naked DNA. (B) VEGF expression in normal and ischemic myocardium injected with the
rPOA/pVEGF polyplex. VEGF level was measured by ELISA one week after injection. Normal,
uninjected group. Data represent the mean ± SD (n = 5 per group). P< 0.05, P< 0.0001.
(TIF)
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